American Journal of Cardiology
Volume 108, Issue 10 , Pages 1499-1507, 15 November 2011

Effect of Bariatric Surgery on Cardiovascular Risk Profile

  • Helen M. Heneghan, MD

      Affiliations

    • Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-444-4794; fax: 216-445-1586
  • ,
  • Shai Meron-Eldar, MD

      Affiliations

    • Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
  • ,
  • Stacy A. Brethauer, MD

      Affiliations

    • Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
    • Endocrine and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
  • ,
  • Philip R. Schauer, MD

      Affiliations

    • Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
    • Endocrine and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio
  • ,
  • James B. Young, MD

      Affiliations

    • Endocrine and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio

Received 9 May 2011; received in revised form 28 June 2011; accepted 28 June 2011. published online 01 September 2011.

Obesity is associated with increased risk for cardiovascular (CV) disease (CVD) and CV mortality. Bariatric surgery has been shown to resolve or improve CVD risk factors, to varying degrees. The objective of this systematic review was to determine the impact of bariatric surgery on CV risk factors and mortality. A systematic review of the published research was performed to evaluate evidence regarding CV outcomes in morbidly obese bariatric patients. Two major databases (PubMed and the Cochrane Library) were searched. The review included all original reports reporting outcomes after bariatric surgery, published in English, from January 1950 to July 2010. In total, 637 studies were identified from the initial screen. After applying inclusion and exclusion criteria, 52 studies involving 16,867 patients were included (mean age 42 years, 78% women). The baseline prevalence of hypertension, diabetes, and dyslipidemia was 49%, 28%, and 46%, respectively. Mean follow-up was 34 months (range 3 to 155), and the average excess weight loss was 52% (range 16% to 87%). Most studies reported significant decreases postoperatively in the prevalence of CV risk factors, including hypertension, diabetes, and dyslipidemia. Mean systolic pressure reduced from to 139 to 124 mm Hg and diastolic pressure from 87 to 77 mm Hg. C-reactive protein decreased, endothelial function improved, and a 40% relative risk reduction for 10-year coronary heart disease risk was observed, as determined by the Framingham risk score. In conclusion, this review highlights the benefits of bariatric surgery in reducing or eliminating risk factors for CVD. It provides further evidence to support surgical treatment of obesity to achieve CVD risk reduction.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  •  Drs. Heneghan and Meron-Eldar contributed equally to this article.

 Dr. Brethauer is a speaker, consultant, and scientific advisory board member for Ethicon Endo-Surgery, Blue Ash, Ohio; is a speaker for Covidien, Mansfield, Massachusetts; and receives research support from Davol, A Bard Company, Warwick, Rhode Island. Dr. Schauer's is a consultant and scientific advisory board member for and has received research support from Ethicon Endo-Surgery; is a member of the board of directors of RemedyMD, Sandy, Utah; is a member of the scientific advisory board of and has received an educational grant from Stryker Endoscopy, San Jose, California; is a member of the scientific advisory board and a consultant for Davol, A Bard Company; is a consultant for and has received an educational grant from W. L. Gore & Associates, Newark, Delaware; has received an educational grant from Baxter International, Deerfield, Illinois; is a member of the scientific advisory boards of BaroSense, Redwood City, California, SurgiQuest, Orange, Connecticut, and Cardinal/Snowden Pencer, Dublin, Ohio; has received an educational grant from Covidien; has received an educational grant from Allergan, Irvine, California; and is a member of the board of directors of Surgical Excellence LLC.

PII: S0002-9149(11)02283-1

doi:10.1016/j.amjcard.2011.06.076

American Journal of Cardiology
Volume 108, Issue 10 , Pages 1499-1507, 15 November 2011